AlTi Global Inc. Lowers Position in Johnson & Johnson $JNJ

Key Points

• AlTi Global Inc. reduced its holdings in Johnson & Johnson by 14.6%, selling 15,770 shares, leaving them with 91,994 shares valued at $15.26 million.
• Multiple institutional investors have increased their positions in Johnson & Johnson, including Apexium Financial LP and Lantz Financial LLC, reflecting significant interest in the company.
• Johnson & Johnson has recently updated its earnings outlook, projecting EPS of $10.800-10.900 for FY 2025, and announced a quarterly dividend of $1.30 to be paid in September.

AlTi Global Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,994 shares of the company's stock after selling 15,770 shares during the period. Johnson & Johnson accounts for 0.4% of AlTi Global Inc.'s investment portfolio, making the stock its 28th largest holding. AlTi Global Inc.'s holdings in Johnson & Johnson were worth $15,256,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of JNJ. Nuveen LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth $1,369,188,000. GAMMA Investing LLC boosted its stake in Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares during the period. Bank of New York Mellon Corp boosted its stake in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 134.5% during the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after purchasing an additional 4,559,147 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after purchasing an additional 2,825,626 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $0.57 during mid-day trading on Friday, hitting $178.20. 9,733,095 shares of the company's stock traded hands, compared to its average volume of 7,556,979. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm's 50 day simple moving average is $168.06 and its 200 day simple moving average is $160.60. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a market cap of $429.15 billion, a PE ratio of 17.88, a price-to-earnings-growth ratio of 2.28 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm posted $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.